If you are attending the DIA Annual meeting in Boston later this month, we invite you to come and see Virtify at booth number 1647.
Not only will you have the opportunity to learn about our newly launched product for Clinical and Regulatory Content Management – Virtify SCM, but we will be making a five dollar contribution to the The One Fund Boston for each visitor to our booth.*
Virtify is proud to call Boston home. As part of our commitment to keeping Boston Strong, we are pleased to be able to support The One Fund Boston which will be used to assist those families of the victims who were killed and the victims who were most seriously affected as a result of the tragic events during the Boston Marathon on April 15, 2013 and related events on April 18th and April 19th.
You may also find it worthwhile to come by our booth to learn about our exciting new product, Virtify SCM. Virtify SCM represents a groundbreaking approach to providing the pharmaceutical industry with powerful capabilities for collaborative / structured authoring and reviewing, content re-use, and workflow and content life cycle management. It has significant benefits across the organization in reducing overall cycle times, improving compliance, increasing efficiency, enhancing quality and improving decision-making. And you can receive more information about it and receive a brief demo during your visit to our booth or download a detailed SCM fact sheet that is available on our website.
If you would like to schedule a private demo or won’t be making it to DIA, but would like to find out more about Virtify SCM, contact Virtify at [email protected], +1 (617) 301-8708.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.